Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novo Nordisk’s Wegovy Pill Wins U.S. Approval  | Contract Pharma

What are you searching for?

Sign in
Breaking News

Novo Nordisk’s Wegovy Pill Wins U.S. Approval 

Becomes the first oral GLP-1 for weight management.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Novo Nordisk

Novo Nordisk received approval from the U.S. FDA for the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.

The Wegovy pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management. The approval is based on the OASIS trial program and the SELECT trial. In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated 16.6% mean weight loss when treatment was adhered to in adult participants with obesity or overweight with one or more comorbidities. The weight loss achieved with the Wegovy pill is similar to that of injectable Wegovy 2.4 mg. One in three people experienced 20% or greater weight loss in the OASIS 4 trial. The safety and tolerability profile of semaglutide was comparable to previous trials with semaglutide for weight management.

Novo Nordisk expects to launch the Wegovy pill in the U.S. in early January 2026. Novo Nordisk has submitted oral semaglutide 25 mg once-daily for obesity to the European Medicines Agency (EMA) and other regulatory authorities during the second half of 2025.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics